Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vera Therapeutics

Explore full profile

A clinical-stage biotechnology company focused on transforming patients’ lives by developing and commercializing treatments for immunological and inflammatory diseases

Brisbane, United StatesFounded 2016Biotech & Life Sciences
Valuation $1.96B Market cap · 2026
Revenue $32M Latest reported FY

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for immunological diseases, with a particular focus on IgA nephropathy, a kidney disorder. The company aims to improve the standard of care for patients suffering from immunologic and rare diseases. Vera Therapeutics operates in the biotechnology sector, targeting healthcare providers and patients in need of advanced therapeutic solutions. The business model revolves around the research, development, and commercialization of novel therapies, generating revenue through licensing agreements and product sales. Vera's pipeline includes MAU868, a groundbreaking neutralizing antibody targeting the BK Virus (BKV), which poses significant risks to immunocompromised patients, such as those undergoing kidney transplants or hematopoietic stem cell transplants. The company holds an exclusive worldwide license from Pfizer for the development and commercialization of MAU868 across all indications. Vera Therapeutics is led by Dr. Andrew Cheng, who brings extensive experience from his tenure at Gilead and other biotech firms. The company is committed to fostering a high-performance work environment and offers a comprehensive rewards package to its employees.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2016
Headquarters
Brisbane, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later7 investors entered at this stage

  • Abingworth
  • Fidelity Investments
  • Alexandria Venture Investments
  • Octagon Capital Partners
  • Citadel
  • Longitude Capital
  • Oxford Finance

Talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Brisbane HQ
Book a demo for the full country breakdown
Web traffic by country
16K monthly visits
across markets
🇺🇸 United States64.4%
🇬🇧 United Kingdom10.6%
🇮🇳 India9.4%
🇪🇸 Spain7.5%
🇯🇵 Japan5.6%
Top 5 markets shown

Patents

Estimated portfolio value
$158k

2 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles